Sage Journals: Discover world-class research

Abstract

Cidofovir is a deoxycytidine monophosphate analog with broad spectrum activity against various deoxyribonucleic acid viruses. Cidofovir is marketed as an injectable for intravenous use; however, there is a topical cidofovir formulation utilized for viral dermatologic infections. Here, we present a case of a successful clearance of a perianal acyclovir resistant and foscarnet refractory herpes simplex virus (HSV1) ulcer in a 34 year-old woman who had undergone allogeneic hematopoietic stem cell transplantation. After 1 week of therapy with cidofovir gel, the patient’s ulcer was clinically improved, and the lesion was negative for herpes simplex virus transcripts by real-time polymerase chain reaction testing. The wound remained herpes simplex virus negative by real-time polymerase chain reaction on repeat testing 1 week later. Based on this and other reports in HIV/AIDS patients, we believe that cidofovir gel has utility in the management of cutaneous, acyclovir-resistant HSV infections.

Keywords

Topical cidofovir acyclovir HSV bone marrow hematopoietic stem cell transplant

Get full access to this article

View all access options for this article.

References

Product information. Vistide [prescribing information], Foster City, CA: Gilead Pharmaceuticals Corporation, August 2011.

McElhiney

. Topical cidofovir for treatment of resistant viral infections. Int J Pharm Comp 2006; 10(5): 324–328.

Lalezari

Schacker

Feinberg

. A randomized, double-blind, placebo-controlled trial of cidofovir gel for the treatment of acyclovir-unresponsive mucocutaneous herpes simplex virus infection in patients with AIDS. J Infect Dis 1997; 176(4): 892–898.

Lateef

. Treatment of acyclovir-resistant, foscarnet-unresponsive HSV infection with topical cidofovir in a child with AIDS. Arch Dermatol 1998; 134(9): 1169–1170.

Sims

. Oral topical cidofovir: novel route of drug delivery in a severely immunosuppressed patient with refractory multidrug-resistant herpes simplex virus infection. Transpl Infect Dis 2007; 9(3): 256–259.

Bienvenu

Martinez

Devergie

. Topical use of cidofovir induced acute renal failure. Transplantation 2002; 73(4): 661–662.

Snoeck

Wellens

Desloovere

. Treatment of severe laryngeal papillomatosis with intralesional injections of cidofovir [(S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine]. J Med Virol 1998; 54(3): 219–225.

Van Cutsem

Snoeck

Van Ranst

. Successful treatment of a squamous papilloma of the hypopharynx-esophagus by local injections of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine. J Med Virol 1995; 45(2): 230–235.

Snoeck

Van Ranst

Andrei

. Treatment of anogenital papillomavirus infections with an acyclic nucleoside phosphonate analogue. N Engl J Med 1995; 333(14): 934–943.

10.

Douglas

Corey

Tyring

. A phase I/II study of cidofovir topical gel for refractory condyloma acuminatum in patients with HIV infection.. Poster presented at: 4th Conference on Retroviruses and Opportunistic Infections. Washington, DC. 22–26 January 1997, poster #334.

11.

Meadows

Tyring

Pavia

. Resolution of recalcitrant molluscum contagiosum virus lesions in human immunodeficiency virus-infected patients treated with cidofovir. Arch Dermatol 1997; 133(8): 987–990.

12.

Davies

Thrasher

Lacey

. Topical cidofovir for severe molluscum contagiosum. Lancet 1999; 353(9169): 2042–2042.

13.

Zabawski

Jr Cockerell

. Topical cidofovir for molluscum contagiosum in children. Pediatr Dermatol 1999; 16(5): 414–415.

14.

Huggins

Smee

Martinez

. Cidofovir(HPMPC) treatment of monkeypox. Abstract presented at: 11th International Conference on Antviral Research. San Diego, California. 5--10 April 1998, abstract #118.

15.

Gilead pharmaceuticals. Gilead announces phase I/II data insufficient for marketing clearance of FORVADE[tm] topical gel to treat refractory herpes in patients with AIDS. Press Release, Foster City, CA, 6 May 1997, May 6, 1997.

16.

Gliead

sciences

. Gilead files NDA for cidofovir gel—drug aimed at refractory genital herpes. Biotechnol Law Report 1997; 16(2): 181–182.

17.

Center for Disease Control. National Institute for Occupational Safety and Health (NIOSH) List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2010. http://www.cdc.gov/niosh/docs/2010-167/pdfs/2010-167.pdf.

18.

Piret

Boivin

. Resistance of herpes simplex viruses to nucleoside analogues: mechanisms, prevalence, and management. Antimicrob Agents Chemother 2011; 55(2): 459–472.

Successful clearance of cutaneous acyclovir-resistant,foscarnet-refractory herpes virus lesions with topical cidofovir in an allogeneic hematopoietic stem cell transplant patient

Abstract

Keywords

Get full access to this article

References